Prime Medicine Inc (NASDAQ: PRME): Can A Stock That’s Down -50.06% YTD Still Be Considered In Loss Territory?

Best AI Stocks

During the last session, Prime Medicine Inc (NASDAQ:PRME)’s traded shares were 0.63 million, with the beta value of the company hitting 2.22. At the end of the trading day, the stock’s price was $4.43, reflecting an intraday gain of 2.91% or $0.13. The 52-week high for the PRME share is $17.20, that puts it down -288.26 from that peak though still a striking 7.22% gain since the share price plummeted to a 52-week low of $4.11. The company’s market capitalization is $530.73M, and the average trade volume was 725.56K shares over the past three months.

Prime Medicine Inc (NASDAQ:PRME) trade information

Prime Medicine Inc (PRME) registered a 2.91% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.91% in intraday trading to $4.43, hitting a weekly high. The stock’s 5-day price performance is -1.88%, and it has moved by -34.54% in 30 days. Based on these gigs, the overall price performance for the year is -66.58%.

Prime Medicine Inc (PRME) estimates and forecasts

Statistics show that Prime Medicine Inc has underperformed its competitors in share price, compared to the industry in which it operates. Prime Medicine Inc (PRME) shares have gone down -27.76% during the last six months, with a year-to-date growth rate less than the industry average at 11.33% against 12.90.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 910k as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 2.04M by the end of current fiscal year.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -193.88%. While earnings are projected to return 18.56% in 2024.

PRME Dividends

Prime Medicine Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Prime Medicine Inc (NASDAQ:PRME)’s Major holders